CANCER:

Mucosal Melanoma

Related cancers:

‹

Melanoma (865)

Ocular Melanoma (86)

Uveal Melanoma (83)

Cutaneous Melanoma (74)

Melanoma (865)

Ocular Melanoma (86)

Uveal Melanoma (83)

Cutaneous Melanoma (74)

›

No biomarker No biomarker	Mucosal Melanoma Mucosal Melanoma	No biomarker No biomarker	Mucosal Melanoma Mucosal Melanoma	toripalimab Sensitive: B - Late Trials	toripalimab Sensitive: B - Late Trials
No biomarker No biomarker	Mucosal Melanoma Mucosal Melanoma	No biomarker No biomarker	Mucosal Melanoma Mucosal Melanoma	ALKS 4230 Sensitive: B - Late Trials	ALKS 4230 Sensitive: B - Late Trials
PD-L1 expression PD-L1 expression	Mucosal Melanoma Mucosal Melanoma	PD-L1 expression PD-L1 expression	Mucosal Melanoma Mucosal Melanoma	toripalimab Sensitive: C2 – Inclusion Criteria	toripalimab Sensitive: C2 – Inclusion Criteria
BRAF mutation BRAF mutation	Mucosal Melanoma Mucosal Melanoma	BRAF mutation BRAF mutation	Mucosal Melanoma Mucosal Melanoma	PD1 inhibitor Sensitive: C3 – Early Trials	PD1 inhibitor Sensitive: C3 – Early Trials
KIT mutation KIT mutation	Mucosal Melanoma Mucosal Melanoma	KIT mutation KIT mutation	Mucosal Melanoma Mucosal Melanoma	PD1 inhibitor Sensitive: C3 – Early Trials	PD1 inhibitor Sensitive: C3 – Early Trials
MDM2 amplification MDM2 amplification	Mucosal Melanoma Mucosal Melanoma	MDM2 amplification MDM2 amplification	Mucosal Melanoma Mucosal Melanoma	ipilimumab Resistant: C3 – Early Trials	ipilimumab Resistant: C3 – Early Trials
MDM4 amplification MDM4 amplification	Mucosal Melanoma Mucosal Melanoma	MDM4 amplification MDM4 amplification	Mucosal Melanoma Mucosal Melanoma	ipilimumab Resistant: C3 – Early Trials	ipilimumab Resistant: C3 – Early Trials
MDM2 amplification MDM2 amplification	Mucosal Melanoma Mucosal Melanoma	MDM2 amplification MDM2 amplification	Mucosal Melanoma Mucosal Melanoma	nivolumab + ipilimumab Resistant: C3 – Early Trials	nivolumab + ipilimumab Resistant: C3 – Early Trials
MDM2 amplification MDM2 amplification	Mucosal Melanoma Mucosal Melanoma	MDM2 amplification MDM2 amplification	Mucosal Melanoma Mucosal Melanoma	nivolumab Resistant: C3 – Early Trials	nivolumab Resistant: C3 – Early Trials
MDM4 amplification MDM4 amplification	Mucosal Melanoma Mucosal Melanoma	MDM4 amplification MDM4 amplification	Mucosal Melanoma Mucosal Melanoma	nivolumab + ipilimumab Resistant: C3 – Early Trials	nivolumab + ipilimumab Resistant: C3 – Early Trials
MDM4 amplification MDM4 amplification	Mucosal Melanoma Mucosal Melanoma	MDM4 amplification MDM4 amplification	Mucosal Melanoma Mucosal Melanoma	nivolumab Resistant: C3 – Early Trials	nivolumab Resistant: C3 – Early Trials
EGFR amplification EGFR amplification	Mucosal Melanoma Mucosal Melanoma	EGFR amplification EGFR amplification	Mucosal Melanoma Mucosal Melanoma	ipilimumab Resistant: C3 – Early Trials	ipilimumab Resistant: C3 – Early Trials
EGFR amplification EGFR amplification	Mucosal Melanoma Mucosal Melanoma	EGFR amplification EGFR amplification	Mucosal Melanoma Mucosal Melanoma	nivolumab Resistant: C3 – Early Trials	nivolumab Resistant: C3 – Early Trials
EGFR amplification EGFR amplification	Mucosal Melanoma Mucosal Melanoma	EGFR amplification EGFR amplification	Mucosal Melanoma Mucosal Melanoma	nivolumab + ipilimumab Resistant: C3 – Early Trials	nivolumab + ipilimumab Resistant: C3 – Early Trials
EGFR amplification EGFR amplification	Mucosal Melanoma Mucosal Melanoma	EGFR amplification EGFR amplification	Mucosal Melanoma Mucosal Melanoma	pembrolizumab Resistant: C3 – Early Trials	pembrolizumab Resistant: C3 – Early Trials
MDM4 amplification MDM4 amplification	Mucosal Melanoma Mucosal Melanoma	MDM4 amplification MDM4 amplification	Mucosal Melanoma Mucosal Melanoma	pembrolizumab Resistant: C3 – Early Trials	pembrolizumab Resistant: C3 – Early Trials
MDM2 amplification MDM2 amplification	Mucosal Melanoma Mucosal Melanoma	MDM2 amplification MDM2 amplification	Mucosal Melanoma Mucosal Melanoma	pembrolizumab Resistant: C3 – Early Trials	pembrolizumab Resistant: C3 – Early Trials
NRAS mutation NRAS mutation	Mucosal Melanoma Mucosal Melanoma	NRAS mutation NRAS mutation	Mucosal Melanoma Mucosal Melanoma	PD1 inhibitor Resistant: C3 – Early Trials	PD1 inhibitor Resistant: C3 – Early Trials
BRAF mutation BRAF mutation	Mucosal Melanoma Mucosal Melanoma	BRAF mutation BRAF mutation	Mucosal Melanoma Mucosal Melanoma	cisplatin + dacarbazine Sensitive: C3 – Early Trials	cisplatin + dacarbazine Sensitive: C3 – Early Trials
NRAS mutation NRAS mutation	Mucosal Melanoma Mucosal Melanoma	NRAS mutation NRAS mutation	Mucosal Melanoma Mucosal Melanoma	cisplatin + temozolomide Sensitive: C3 – Early Trials	cisplatin + temozolomide Sensitive: C3 – Early Trials
KIT mutation KIT mutation	Mucosal Melanoma Mucosal Melanoma	KIT mutation KIT mutation	Mucosal Melanoma Mucosal Melanoma	cisplatin + temozolomide Sensitive: C3 – Early Trials	cisplatin + temozolomide Sensitive: C3 – Early Trials
BRAF mutation BRAF mutation	Mucosal Melanoma Mucosal Melanoma	BRAF mutation BRAF mutation	Mucosal Melanoma Mucosal Melanoma	cisplatin + temozolomide Sensitive: C3 – Early Trials	cisplatin + temozolomide Sensitive: C3 – Early Trials
NRAS mutation NRAS mutation	Mucosal Melanoma Mucosal Melanoma	NRAS mutation NRAS mutation	Mucosal Melanoma Mucosal Melanoma	cisplatin + dacarbazine Sensitive: C3 – Early Trials	cisplatin + dacarbazine Sensitive: C3 – Early Trials
KIT mutation KIT mutation	Mucosal Melanoma Mucosal Melanoma	KIT mutation KIT mutation	Mucosal Melanoma Mucosal Melanoma	cisplatin + dacarbazine Sensitive: C3 – Early Trials	cisplatin + dacarbazine Sensitive: C3 – Early Trials
KIT L576P KIT L576P	Mucosal Melanoma Mucosal Melanoma	KIT L576P KIT L576P	Mucosal Melanoma Mucosal Melanoma	sorafenib Resistant: C4 – Case Studies	sorafenib Resistant: C4 – Case Studies
KIT L576P KIT L576P	Mucosal Melanoma Mucosal Melanoma	KIT L576P KIT L576P	Mucosal Melanoma Mucosal Melanoma	temsirolimus Resistant: C4 – Case Studies	temsirolimus Resistant: C4 – Case Studies
KIT L576P KIT L576P	Mucosal Melanoma Mucosal Melanoma	KIT L576P KIT L576P	Mucosal Melanoma Mucosal Melanoma	imatinib Resistant: C4 – Case Studies	imatinib Resistant: C4 – Case Studies

Mucosal Melanoma

Associations(27)

Associations
(27)